Department of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Department of Cardiac Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
PeerJ. 2023 Jan 25;11:e14610. doi: 10.7717/peerj.14610. eCollection 2023.
Lenvatinib has become a first-line drug in the treatment of advanced hepatocellular carcinoma (HCC). Investigating its use in combination with other agents is of great significance to improve the sensitivity and durable response of Lenvatinib in advanced HCC patients. Vitamin C (L-ascorbic acid, ascorbate, VC) is an important natural antioxidant, which has been reported to show suppressive effects in cancer treatment. Here, we investigated the effect of the combination of VC and Lenvatinib in HCC cells . We found that treatment of VC alone significantly inhibited the proliferation, migration and invasion in HCC cells. Additionally, VC was strongly synergistic with Lenvatinib in inhibition of the proliferative, migratory and invasive capacities of HCC cells . In conclusion, our results demonstrate that the combination of VC and Lenvatinib has synergistic antitumor activities against HCC cells, providing a promising therapeutic strategy to improve the prognosis of HCC patients.
仑伐替尼已成为治疗晚期肝细胞癌（HCC）的一线药物。研究其与其他药物联合使用对于提高晚期 HCC 患者仑伐替尼的敏感性和持久反应具有重要意义。维生素 C（L-抗坏血酸、抗坏血酸盐、VC）是一种重要的天然抗氧化剂，据报道其在癌症治疗中具有抑制作用。在这里，我们研究了 VC 与仑伐替尼联合应用于 HCC 细胞的效果。我们发现，单独使用 VC 治疗可显著抑制 HCC 细胞的增殖、迁移和侵袭。此外，VC 与仑伐替尼联用在抑制 HCC 细胞的增殖、迁移和侵袭能力方面具有很强的协同作用。总之，我们的结果表明，VC 和仑伐替尼联合应用对 HCC 细胞具有协同抗肿瘤活性，为改善 HCC 患者的预后提供了一种有前途的治疗策略。
